Kaposi's Sarcoma-Associated Herpesvirus and Host Interaction by the Complement System.
KSHV
complement system
innate immunity
membrane attack complex
virus–host interaction
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
03 Apr 2020
03 Apr 2020
Historique:
received:
20
02
2020
revised:
19
03
2020
accepted:
02
04
2020
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
9
4
2020
Statut:
epublish
Résumé
Kaposi's sarcoma-associated herpesvirus (KSHV) modulates the immune response to allow the virus to establish persistent infection in the host and facilitate the development of KSHV-associated cancer. The complement system has a central role in the defense against pathogens. Hence, KSHV has adopted an evasion strategy for complement attack using the viral protein encoded by KSHV open reading frame 4. However, despite this defense mechanism, the complement system appears to become activated in KSHV-infected cells as well as in the region surrounding Kaposi's sarcoma tumors. Given that the complement system can affect cell fate as well as the inflammatory microenvironment, complement activation is likely associated with KSHV pathogenesis. A better understanding of the interplay between KSHV and the complement system may, therefore, translate into the development of novel therapeutic interventions for KSHV-associated tumors. In this review, the mechanisms and functions of complement activation in KSHV-infected cells are discussed.
Identifiants
pubmed: 32260199
pii: pathogens9040260
doi: 10.3390/pathogens9040260
pmc: PMC7237997
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : National Research Foundation of Korea
ID : NRF-2019R1A2C2083947
Références
Tissue Antigens. 2010 Nov;76(5):341-51
pubmed: 20860583
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8789-94
pubmed: 27432952
J Virol. 1992 Jul;66(7):4013-27
pubmed: 1602532
Semin Cell Dev Biol. 2017 Dec;72:124-132
pubmed: 28647534
Ann Oncol. 2009 Apr;20(4):775-9
pubmed: 19179554
Exp Clin Immunogenet. 1997;14(1):16-8
pubmed: 9187918
J Virol. 2006 Apr;80(8):4068-78
pubmed: 16571823
Am J Pathol. 1997 Jun;150(6):2019-31
pubmed: 9176395
Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):628-32
pubmed: 1731333
PLoS One. 2009 Aug 26;4(8):e6782
pubmed: 19707565
J Virol. 2003 Sep;77(18):9738-49
pubmed: 12941882
Infect Immun. 2011 Feb;79(2):724-31
pubmed: 21134964
Front Immunol. 2012 Dec 10;3:368
pubmed: 23233853
J Immunol. 2000 Aug 15;165(4):2183-9
pubmed: 10925305
Adv Protein Chem. 1979;33:1-71
pubmed: 396780
N Engl J Med. 1995 May 4;332(18):1181-5
pubmed: 7700310
Adv Drug Deliv Rev. 2011 Sep 16;63(12):965-75
pubmed: 21704094
Oncotarget. 2017 Sep 23;9(85):35517-35527
pubmed: 30473747
J Exp Med. 2003 Sep 15;198(6):913-23
pubmed: 12975457
Eur J Immunol. 1990 Dec;20(12):2643-50
pubmed: 1702720
J Virol. 1992 Jun;66(6):3937-40
pubmed: 1316492
Cell Host Microbe. 2019 Apr 10;25(4):482-483
pubmed: 30974082
Cancer Res. 2008 Sep 1;68(17):6963-8
pubmed: 18757410
FASEB J. 2014 Mar;28(3):1511-25
pubmed: 24344329
J Microbiol Biotechnol. 2016 Mar;26(3):618-26
pubmed: 26699745
Virology. 2011 Mar 15;411(2):362-73
pubmed: 21292294
J Biol Chem. 2011 Jul 8;286(27):23717-24
pubmed: 21566137
Nat Rev Nephrol. 2016 Jul;12(7):383-401
pubmed: 27211870
Mol Immunol. 2013 Dec 15;56(3):191-8
pubmed: 23816404
J Innate Immun. 2018;10(2):94-105
pubmed: 29237166
Immunopharmacology. 1999 May;42(1-3):15-21
pubmed: 10408361
Adv Exp Med Biol. 2008;632:71-9
pubmed: 19025115
J Immunol. 2007 Aug 15;179(4):2600-8
pubmed: 17675523
Cell Immunol. 1976 Mar 1;22(1):98-109
pubmed: 1277295
Transl Biomed. 2010;1(2):
pubmed: 23082307
Front Immunol. 2013 Apr 23;4:93
pubmed: 23630525
Sci Rep. 2018 Apr 3;8(1):5415
pubmed: 29615744
Mol Immunol. 1986 Jan;23(1):87-96
pubmed: 3634188
J Clin Invest. 2010 Apr;120(4):939-49
pubmed: 20364091
Nat Rev Microbiol. 2008 Feb;6(2):132-42
pubmed: 18197169
J Immunol. 2004 Jan 15;172(2):1198-202
pubmed: 14707097
Front Immunol. 2019 May 21;10:1074
pubmed: 31164885
Mol Immunol. 2003 Jan;39(11):669-75
pubmed: 12493642
Future Virol. 2008 May;3(3):225-233
pubmed: 21218140
Front Microbiol. 2017 Apr 20;8:613
pubmed: 28473805
Lymphokine Cytokine Res. 1993 Jun;12(3):167-72
pubmed: 7688580
J Biol Chem. 2004 Oct 22;279(43):45093-101
pubmed: 15304516
J Immunol Methods. 2014 Dec 15;415:57-62
pubmed: 25260423
PLoS Pathog. 2014 Sep 25;10(9):e1004412
pubmed: 25254972
Mol Immunol. 2007 Jan;44(1-3):11-22
pubmed: 16905191
Scand J Immunol. 1991 Jun;33(6):667-71
pubmed: 2047760
Blood. 2002 Apr 1;99(7):2331-6
pubmed: 11895764
Ann N Y Acad Sci. 1983;421:291-8
pubmed: 6586103
J Cell Sci. 2013 Jul 1;126(Pt 13):2903-13
pubmed: 23613465
Onco Targets Ther. 2018 Jun 28;11:3747-3754
pubmed: 29988764
Oncotarget. 2017 Oct 9;8(59):99841-99860
pubmed: 29245944
J Clin Lab Anal. 2004;18(1):1-8
pubmed: 14730550
J Virol. 2003 Jan;77(1):592-9
pubmed: 12477863
Springer Semin Immunopathol. 1983;6(2-3):213-30
pubmed: 6314572
J Biol Chem. 2003 Mar 14;278(11):9283-9
pubmed: 12645526
N Engl J Med. 2008 Jan 31;358(5):535-6; author reply 536
pubmed: 18234764
Vaccine. 2007 Nov 23;25(48):8102-9
pubmed: 17964697
Eur J Immunol. 1992 May;22(5):1207-13
pubmed: 1577063
Inflamm Res. 2010 Aug;59(8):659-66
pubmed: 20217457
J Virol. 2001 Sep;75(17):8240-50
pubmed: 11483769
J Clin Invest. 2017 Mar 1;127(3):780-789
pubmed: 28248200
BMC Microbiol. 2008 Dec 18;8:229
pubmed: 19094203
Mol Immunol. 2008 Mar;45(5):1199-207
pubmed: 17961651
J Virol. 2003 Mar;77(6):3878-81
pubmed: 12610165
J Cell Mol Med. 2019 Aug;23(8):5654-5671
pubmed: 31184423
J Virol. 1999 Sep;73(9):7658-70
pubmed: 10438856
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879
J Clin Invest. 1979 Aug;64(2):428-33
pubmed: 457861
Curr Top Microbiol Immunol. 1985;121:159-87
pubmed: 3936681